Versant Capital Management, Inc Neurocrine Biosciences Inc Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Versant Capital Management, Inc holds 517 shares of NBIX stock, worth $66,113. This represents 0.01% of its overall portfolio holdings.
Number of Shares
517
Previous 409
26.41%
Holding current value
$66,113
Previous $45,000
42.22%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
97.6MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.81 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.27 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$708 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$622 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$342 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $12.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...